
As the most common serious injury affecting the elderly, hip fractures carry a profound clinical and socioeconomic burden. These patients often have complex co-morbidities where medical optimization must be balanced against the requirement for urgent intervention. In recent times, these challenges have been addressed by developing a comprehensive hip fracture programme, consisting of coordination between multiple professionals for management from admission to follow-up after discharge.Anaesthetic management of fractured neck of femur has evolved into a complex model of perioperative geriatric care where timely intervention, individualized technique and advanced analgesia are the pillars of modern management, aimed at restoring the patient to their pre-fracture level of independence. With cases projected to rise and more patients presenting with frailty, achieving optimal perioperative management is critical to reducing morbidity and mortality.
Reconstructive plastic surgery involving flap reconstruction requires holistic care delivered by a multidisciplinary team. Indications for plastic reconstructive surgery are varied, incorporating management of congenital defects, traumatic injuries or malignant processes. This encompasses a heterogenous demographic of patients spanning a wide range of ages and exhibiting a variety of co-morbidities. Appropriate patient selection is an important element of the decision-making process which influences patient outcomes. Meticulous surgical techniques, often involving microvascular anastomosis, are required to achieve optimal outcomes. Surgical procedures may be prolonged and maintaining physiological homeostasis is an important anaesthetic goal. Anaesthetic management focuses on creating the conditions for flap success by optimizing perfusion, delivering adequate oxygen to the flap and achieving normothermia. Regional anaesthetic techniques may confer benefits in promoting flap perfusion via peripheral sympathectomy and as an analgesic adjunct. This paper will outline the common techniques of reconstructive surgery and consider the role of anaesthesia in optimizing patients undergoing major reconstructive surgery.
The therapeutics landscape for joint and muscle disease has and continues to evolve rapidly, with conventional synthetic, biologic, and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) posing distinct considerations for perioperative and critical-care management. Infection risk that is secondary to immunosuppression remains a primary concern, as patients are susceptible to opportunistic infections and likely to have a blunted inflammatory response. In addition, drug-specific toxicities and interactions can influence perioperative and critical-care decision-making, as recipients are vulnerable to organ dysfunction, altered drug metabolism and haematological disorders. Adjustment to therapy in the context of surgery and infection are frequently required, though limited guidance may necessitate specialist rheumatology input. This article reviews commonly used therapeutics in joint and muscle disease, their indications, adverse effects, perioperative guidance, anaesthetic considerations and critical care relevance.